Parapres Comp
Candesartan 32 mg / Hydrochlorothiazide 12.5 mg – High-Strength Combination for Hypertension
Quick Facts About Parapres Comp
Key Takeaways About Parapres Comp
- High-strength combination therapy: Delivers the maximum candesartan dose (32 mg) paired with a low-dose thiazide diuretic (12.5 mg) for patients needing intensified blood pressure control
- Absolutely contraindicated in pregnancy: Must not be used during pregnancy as it can cause serious foetal harm – discontinue immediately if pregnancy is detected or planned
- Electrolyte monitoring is essential: Hydrochlorothiazide can deplete potassium, sodium, and magnesium while candesartan tends to raise potassium – periodic blood tests are required
- Take once daily at the same time: Provides 24-hour blood pressure control; swallow whole with water, with or without food, ideally in the morning to limit nocturnal urination
- Stay hydrated and protect your skin: The diuretic increases fluid loss – drink adequate water, avoid excessive sun exposure, and use sunscreen to reduce the risk of photosensitivity and skin cancer
What Is Parapres Comp and What Is It Used For?
Parapres Comp is a combination tablet containing candesartan cilexetil 32 mg and hydrochlorothiazide 12.5 mg. It is prescribed to treat essential hypertension (high blood pressure) in adults whose blood pressure is not sufficiently controlled by the highest dose of candesartan monotherapy. It is not recommended as a first-line treatment for hypertension.
Parapres Comp belongs to the therapeutic category of fixed-dose combination antihypertensives. It combines two well-established classes of blood pressure medication into a single tablet: an angiotensin II receptor blocker (ARB) and a thiazide diuretic. The combination approach is strongly supported by international guidelines from the European Society of Cardiology (ESC), the American Heart Association (AHA), the International Society of Hypertension (ISH), and the World Health Organization (WHO), all of which recommend two-drug combination therapy as the preferred initial or intensification strategy for most adults with grade 2 or grade 3 hypertension.
Candesartan cilexetil, the ARB component, works by selectively and competitively blocking the angiotensin II type 1 (AT1) receptor. Angiotensin II is one of the most potent vasoconstrictors in the body and is also responsible for stimulating the adrenal glands to release aldosterone, a hormone that promotes the retention of sodium and water. When candesartan blocks the AT1 receptor, blood vessels relax and widen (vasodilation), aldosterone release is reduced, and the kidneys excrete more sodium. The net result is a steady and sustained fall in blood pressure. Candesartan cilexetil itself is a prodrug; during absorption in the intestinal tract, it is rapidly hydrolysed to the active compound candesartan. The 32 mg dose used in Parapres Comp represents the highest commonly prescribed candesartan strength, providing maximal AT1 receptor blockade.
Hydrochlorothiazide (HCTZ), the diuretic component, exerts its antihypertensive effect by inhibiting the sodium-chloride symporter in the distal convoluted tubule of the nephron. This action prevents the reabsorption of sodium and chloride back into the bloodstream, resulting in increased urinary excretion of water and electrolytes. In the short term, this lowers blood pressure by reducing circulating blood volume. In the long term, hydrochlorothiazide also produces direct vasodilation and reduces peripheral vascular resistance through mechanisms involving altered vascular smooth muscle responsiveness. The low 12.5 mg dose used in Parapres Comp retains most of the antihypertensive benefit of thiazides while substantially reducing the risk of metabolic side effects such as hypokalaemia, hyperuricaemia, and glucose intolerance.
The pharmacological rationale for combining candesartan and hydrochlorothiazide is both mechanistic and clinical. Thiazide diuretics reduce plasma volume, which in turn activates the renin-angiotensin-aldosterone system (RAAS) as a compensatory response. This RAAS activation partially counteracts the blood pressure-lowering effect of the diuretic. Candesartan neutralises this compensatory response by blocking the downstream AT1 receptor, so the full antihypertensive potential of the diuretic is preserved. In addition, candesartan helps mitigate hydrochlorothiazide-induced potassium loss by promoting potassium retention at the renal tubule, reducing the risk of hypokalaemia. The combined effect is synergistic, producing significantly greater blood pressure reduction than either component used alone and allowing both drugs to work at effective but tolerable doses.
Parapres Comp is used when a patient has been maximised on candesartan 32 mg monotherapy but blood pressure targets remain unmet. It can also be used for patients already stabilised on the separate components, as a convenience step to reduce pill burden and improve adherence. Multiple randomised controlled trials and meta-analyses have demonstrated that patients switched from candesartan monotherapy to candesartan/HCTZ combinations achieve additional systolic blood pressure reductions of 8–12 mmHg and diastolic reductions of 4–7 mmHg on average, bringing many patients to guideline-recommended targets.
Hypertension affects approximately 1.28 billion adults worldwide according to the World Health Organization (WHO), and only around 1 in 5 adults with hypertension have it under control. It is the leading modifiable risk factor for cardiovascular disease, stroke, chronic kidney disease, and premature death. The 2023 ESH Hypertension Guidelines recommend starting combination therapy with two agents for most patients with grade 2 hypertension or higher, as this approach achieves target blood pressure more quickly and with fewer dose adjustments than sequential monotherapy. Single-pill combinations such as Parapres Comp have been shown to improve treatment adherence by up to 50 percent compared with separate tablets.
What Should You Know Before Taking Parapres Comp?
Before starting Parapres Comp, inform your doctor about all medical conditions, especially kidney disease, liver problems, diabetes, gout, and any known allergies, including sulfonamide allergy. Parapres Comp must not be used during pregnancy, in patients with severe kidney or liver impairment, or together with aliskiren in diabetic patients.
Contraindications
You should not take Parapres Comp if any of the following apply to you:
- Pregnancy or planning to become pregnant: Parapres Comp can cause severe foetal injury or death, particularly during the second and third trimesters. If pregnancy is confirmed, discontinue immediately
- Breastfeeding: Both components pass into breast milk; the medication is not recommended during breastfeeding
- Known hypersensitivity to candesartan, hydrochlorothiazide, or any other sulfonamide-derived drug: Hydrochlorothiazide is a sulfonamide derivative, and cross-reactivity may occur in patients with a history of severe sulfonamide allergy
- Severe renal impairment (eGFR below 30 mL/min/1.73 m²) or anuria (no urine output) – the kidneys cannot respond adequately to the diuretic
- Severe hepatic impairment and/or cholestasis: Candesartan is partly eliminated via bile, and impaired hepatobiliary function can cause accumulation of the drug
- Refractory hypokalaemia or clinically significant hypercalcaemia: Hydrochlorothiazide will worsen these electrolyte imbalances
- Symptomatic hyperuricaemia or gout: Hydrochlorothiazide can trigger acute gout attacks
- Severe hyponatraemia: The diuretic component may further deplete sodium levels
- Concomitant use with aliskiren in patients with diabetes mellitus or moderate-to-severe renal impairment (eGFR below 60 mL/min/1.73 m²) – dual RAAS blockade markedly increases the risk of hypotension, hyperkalaemia, and renal failure
Parapres Comp must not be used at any stage of pregnancy. Drugs acting on the renin-angiotensin system are known to cause oligohydramnios (reduced amniotic fluid), foetal kidney failure, skull ossification defects, limb contractures, pulmonary hypoplasia, and neonatal death. If you become pregnant while taking this medicine, stop taking it immediately and contact your doctor to discuss pregnancy-safe alternatives such as labetalol, methyldopa, or nifedipine.
Warnings and Precautions
Talk to your doctor or pharmacist before taking Parapres Comp if you have, or have had, any of the following:
- Kidney problems: Renal function and potassium should be monitored periodically. The combination of an ARB and a diuretic can impair kidney function, particularly in patients with bilateral renal artery stenosis, pre-existing chronic kidney disease, severe heart failure, or volume depletion from dehydration
- Heart failure: Parapres Comp should be initiated cautiously and under close medical supervision. Blood pressure, renal function, and potassium levels need close monitoring, particularly during the first weeks of therapy and after dose adjustments
- Aortic or mitral valve stenosis, hypertrophic cardiomyopathy, or pericardial disease: Use with caution due to the risk of excessive blood pressure reduction and reduced coronary perfusion
- Diabetes mellitus: Hydrochlorothiazide can increase blood glucose levels and may impair glucose tolerance. Diabetic patients may require adjustment of insulin or oral hypoglycaemic therapy. On the other hand, candesartan may have a modest protective effect on kidney function and cardiovascular outcomes in patients with diabetic nephropathy
- Gout or elevated uric acid: Thiazide diuretics reduce renal uric acid excretion and can precipitate gout attacks. Patients with a history of gout should be closely monitored
- Systemic lupus erythematosus (SLE): Thiazide diuretics have been reported to exacerbate or activate SLE in susceptible individuals
- Primary hyperaldosteronism: Patients with this condition generally do not respond well to antihypertensives acting on the renin-angiotensin system; alternative treatments should be considered
- Scheduled surgery or anaesthesia: Inform your surgeon and anaesthetist that you are taking Parapres Comp. It may interact with anaesthetic agents and contribute to excessive intraoperative hypotension; some clinicians advise temporarily holding the dose on the morning of surgery
- Electrolyte imbalances: Regular measurement of serum sodium, potassium, magnesium, calcium, chloride, and bicarbonate is recommended, particularly during the first few months of treatment and after any dose adjustment
- Acute myopia and secondary angle-closure glaucoma: Hydrochlorothiazide has been rarely associated with idiosyncratic ocular reactions, typically within hours to weeks of starting treatment. Untreated, this can lead to permanent vision loss
- Non-melanoma skin cancer: Long-term and high cumulative doses of hydrochlorothiazide have been associated with an increased risk of basal cell carcinoma and squamous cell carcinoma – minimise sun exposure and use adequate sun protection
Pregnancy and Breastfeeding
Pregnancy: Parapres Comp is absolutely contraindicated throughout pregnancy. Exposure to ARBs during the second and third trimesters is associated with severe and potentially fatal foetal abnormalities, including renal dysfunction, oligohydramnios, skull ossification defects, pulmonary hypoplasia, limb contractures, and neonatal hypotension. First-trimester exposure is also associated with an increased risk of cardiovascular and central nervous system malformations. Women of childbearing potential should use effective contraception while taking Parapres Comp. If pregnancy is planned or confirmed, the medication must be stopped immediately and a pregnancy-safe antihypertensive substituted.
Breastfeeding: Candesartan is excreted in milk in animal studies, and hydrochlorothiazide passes into human breast milk in low concentrations. Due to the theoretical risk of adverse effects in the nursing infant (hypotension, hyperkalaemia, jaundice from displaced bilirubin, and reduced milk supply from the diuretic), Parapres Comp is not recommended during breastfeeding, especially in preterm or neonatal infants. Your doctor will recommend an alternative, such as nifedipine or labetalol, that is compatible with breastfeeding.
Driving and Operating Machinery
Dizziness, fatigue, and orthostatic hypotension have been reported in patients taking Parapres Comp, particularly at the start of treatment, after dose adjustments, during hot weather, after alcohol consumption, or when combined with other medications that lower blood pressure. If you experience these symptoms, do not drive or operate heavy machinery until they resolve. Individual responses to treatment vary considerably, so assess your own reaction to the medicine before engaging in activities that require full alertness.
How Does Parapres Comp Interact with Other Drugs?
Parapres Comp can interact with a wide range of medications, including lithium, non-steroidal anti-inflammatory drugs (NSAIDs), potassium supplements, other antihypertensives, and certain diabetes drugs. Both the candesartan and hydrochlorothiazide components have their own interaction profiles, so it is essential to disclose every prescription medication, over-the-counter product, supplement, and herbal remedy you are taking.
The interaction profile of Parapres Comp reflects the combined pharmacology of its two active ingredients. Candesartan primarily interacts with drugs that affect the renin-angiotensin-aldosterone system, potassium balance, or renal haemodynamics, while hydrochlorothiazide interacts with drugs affected by fluid status and electrolyte changes, drugs cleared by the kidney, and drugs with narrow therapeutic indices. Some interactions are clinically significant and may require dose adjustments, additional monitoring, or avoidance of the combination altogether.
Major Interactions
| Drug | Category | Effect | Recommendation |
|---|---|---|---|
| Lithium | Mood stabiliser | Both ARBs and thiazide diuretics reduce lithium renal clearance, significantly increasing plasma lithium levels and the risk of toxicity (tremor, confusion, arrhythmias) | Avoid combination where possible. If unavoidable, monitor lithium levels very frequently and adjust the lithium dose |
| Aliskiren (in diabetic patients) | Direct renin inhibitor | Dual blockade of the RAAS increases the risk of hypotension, hyperkalaemia, and renal impairment | Contraindicated in diabetic patients. Avoid in patients with moderate-to-severe renal impairment (eGFR <60 mL/min/1.73 m²) |
| Potassium supplements and potassium-sparing diuretics (spironolactone, eplerenone, amiloride, triamterene) | Electrolyte supplements / Diuretics | Candesartan promotes potassium retention; combination markedly increases the risk of dangerous hyperkalaemia, particularly in patients with impaired renal function | Avoid unless clearly indicated (e.g. documented hypokalaemia). Use only under close medical supervision with frequent potassium monitoring |
| ACE inhibitors (ramipril, enalapril, lisinopril, perindopril) | Antihypertensive (RAAS inhibitor) | Dual RAAS blockade – substantially increased risk of hypotension, acute kidney injury, and hyperkalaemia with no additional cardiovascular benefit | Generally avoid. If combination is essential (e.g., in proteinuric kidney disease), use only under specialist supervision with close monitoring |
| Salt substitutes containing potassium | Dietary product | Many low-sodium salt alternatives replace sodium chloride with potassium chloride, which can raise serum potassium to dangerous levels when combined with Parapres Comp | Avoid potassium-based salt substitutes unless specifically approved by your doctor after electrolyte assessment |
Moderate Interactions
| Drug | Category | Effect | Recommendation |
|---|---|---|---|
| NSAIDs (ibuprofen, naproxen, diclofenac, indomethacin) including COX-2 inhibitors | Anti-inflammatory / Analgesic | Can blunt the antihypertensive effect and cause acute kidney injury (“triple whammy” when combined with a diuretic) | Use lowest effective NSAID dose for shortest duration. Monitor blood pressure, renal function, and potassium. Prefer paracetamol where possible |
| Digoxin | Cardiac glycoside | Diuretic-induced hypokalaemia and hypomagnesaemia sensitise the heart to digoxin and increase the risk of arrhythmias and digoxin toxicity | Monitor electrolytes (potassium, magnesium) and digoxin levels regularly; replace electrolytes as needed |
| Metformin and other antidiabetic drugs | Antidiabetic | Hydrochlorothiazide may raise blood glucose levels, reducing antidiabetic efficacy. Rare risk of lactic acidosis with metformin if renal function deteriorates | Monitor fasting glucose, HbA1c, and renal function. Adjust antidiabetic therapy as needed |
| Carbamazepine and SSRIs | Anticonvulsant / Antidepressant | Increased risk of symptomatic hyponatraemia (low sodium) when combined with hydrochlorothiazide | Monitor sodium levels; watch for symptoms such as confusion, drowsiness, nausea, and new-onset seizures |
| Corticosteroids and ACTH | Anti-inflammatory / Hormone | Can reduce the antihypertensive effect and worsen hydrochlorothiazide-induced potassium and magnesium loss | Monitor blood pressure and potassium during concurrent use; replace electrolytes as needed |
| Antiarrhythmics of class Ia and III (quinidine, amiodarone, sotalol) | Cardiac antiarrhythmic | Hypokalaemia from HCTZ can increase the risk of torsades de pointes with QT-prolonging antiarrhythmics | Monitor ECG (QT interval), electrolytes; correct hypokalaemia promptly |
| Calcium salts and vitamin D | Supplements | Thiazides reduce calcium excretion and may cause hypercalcaemia when combined with calcium or vitamin D supplements | Monitor serum calcium periodically, particularly in elderly patients |
| Alcohol, barbiturates, opioids, and CNS depressants | CNS depressant | Potentiates the antihypertensive effect; increases risk of orthostatic hypotension, dizziness, and falls | Limit alcohol intake. Stand up slowly from sitting or lying positions, especially at the start of treatment |
This is not a complete list of drug interactions. Always tell your doctor and pharmacist about all prescription and over-the-counter medicines, vitamins, herbal supplements, and dietary products you are taking. Some herbal supplements, such as liquorice root (glycyrrhiza), St John's wort, and ginkgo biloba, can interact with Parapres Comp or with drugs used alongside it. Liquorice root in particular can cause potassium depletion and raise blood pressure, directly opposing the effects of Parapres Comp.
What Is the Correct Dosage of Parapres Comp?
The usual dose of Parapres Comp is one tablet (32 mg candesartan/12.5 mg hydrochlorothiazide) taken once daily by mouth, with or without food. Parapres Comp is used when adequate blood pressure control has not been achieved on candesartan 32 mg monotherapy. Always follow your doctor's prescribed dose and never adjust it yourself.
Parapres Comp is intended as a step-up therapy, not as initial treatment for newly diagnosed hypertension. In most patients, treatment is started with candesartan monotherapy and titrated to 32 mg daily. If blood pressure targets are still not met after 4–6 weeks at the maximum tolerated candesartan dose, your doctor may switch you to Parapres Comp to add the complementary effect of a low-dose thiazide diuretic. The total daily dose should not exceed one Parapres Comp tablet.
Adults
Standard Adult Dosage
One tablet of Parapres Comp (32 mg/12.5 mg) taken once daily by mouth, with or without food. The tablet should be swallowed whole with a glass of water, ideally at the same time each day. Many clinicians prefer morning administration to avoid nighttime urination related to the diuretic effect. If you experience gastric upset, taking the tablet with food may improve tolerability without affecting absorption meaningfully.
The full antihypertensive effect of Parapres Comp is typically reached within 4 to 6 weeks of continuous daily dosing. If blood pressure remains above target, your doctor may consider a higher-strength combination (32 mg/25 mg, where available), add a third antihypertensive from a different class (typically a calcium channel blocker such as amlodipine), or investigate causes of treatment-resistant hypertension such as secondary hypertension, non-adherence, obstructive sleep apnoea, or excess salt intake.
Elderly Patients
Elderly Dosage Considerations
No specific dose reduction is generally required for elderly patients based on age alone. However, elderly patients are more susceptible to orthostatic hypotension (dizziness on standing up), volume depletion, electrolyte imbalances, and acute kidney injury. Treatment should be initiated cautiously, typically after optimising monotherapy first. Renal function, blood pressure (including standing measurements), and electrolytes should be monitored more frequently during the first weeks of therapy and after any dose change. Adequate fluid intake is important, particularly in hot weather or during acute illness with fever, vomiting, or diarrhoea.
Use in Children and Adolescents
Paediatric Information
Parapres Comp is not recommended for children or adolescents under 18 years of age. The safety and efficacy of the fixed-dose combination have not been established in this age group, and the 32 mg candesartan component exceeds typical paediatric doses. For paediatric hypertension, the individual components may be used separately under the supervision of a paediatric nephrologist or cardiologist, with doses adjusted based on weight and age.
Dose Adjustments for Kidney and Liver Impairment
Renal and Hepatic Considerations
Mild-to-moderate kidney impairment (eGFR 30–60 mL/min/1.73 m²): Parapres Comp may be used with caution. Renal function and electrolytes should be monitored closely, particularly during initiation and after dose changes. The diuretic effect of hydrochlorothiazide diminishes as kidney function declines.
Severe kidney impairment (eGFR <30 mL/min/1.73 m²) or anuria: Parapres Comp is contraindicated. Thiazide diuretics are largely ineffective at this level of renal impairment, and combination ARB therapy may worsen kidney function.
Mild-to-moderate liver impairment: Candesartan should be started at a lower dose before switching to the fixed combination. Parapres Comp may be used with careful monitoring once the patient is stabilised.
Severe liver impairment or cholestasis: Parapres Comp is contraindicated, as candesartan is partly excreted via the bile.
Volume- or salt-depleted patients: Before starting Parapres Comp, any volume depletion should be corrected, or treatment should be initiated cautiously under close observation to avoid symptomatic hypotension.
Missed Dose
If you forget to take your Parapres Comp tablet, take it as soon as you remember, provided it is not close to the time of your next scheduled dose. If it is nearly time for the next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one. A single missed dose is unlikely to cause a dramatic rise in blood pressure because Parapres Comp provides sustained 24-hour control, but consistently missing doses will reduce the effectiveness of your treatment and increase cardiovascular risk over time. If you struggle with adherence, speak to your doctor or pharmacist about strategies such as pill organisers, phone reminders, or associating dosing with a daily routine.
Overdose
In case of suspected overdose, seek medical attention immediately or contact your local poison control centre. Symptoms of Parapres Comp overdose may include severe dizziness, fainting, pronounced hypotension, rapid or irregular heartbeat, and electrolyte disturbances such as hypokalaemia, hyponatraemia, or dehydration. Treatment is primarily supportive and symptomatic, including intravenous fluid replacement to restore circulating volume, careful electrolyte correction, and continuous cardiac monitoring. Candesartan is unlikely to be removed by haemodialysis due to its high protein binding, while hydrochlorothiazide can be partially removed by dialysis.
If you or someone else has taken more Parapres Comp than prescribed, call emergency services immediately. Symptoms may include severe hypotension, dizziness, fainting, weakness, muscle cramps, confusion, irregular heartbeat, and dehydration. Bring the medicine packaging with you so emergency staff can identify the exact product. Early medical intervention is critical, particularly in elderly patients and those with pre-existing kidney or cardiovascular disease.
What Are the Side Effects of Parapres Comp?
Like all medicines, Parapres Comp can cause side effects, although not everyone gets them. The most frequently reported side effects are dizziness, headache, fatigue, and increased urination. Serious but rare side effects include severe allergic reactions, angioedema, significant electrolyte disturbances, acute kidney injury, and acute myopia or glaucoma.
The side effect profile of Parapres Comp reflects the combined effects of both candesartan and hydrochlorothiazide. In clinical trials and real-world studies, the combination is generally well tolerated, with most adverse events mild to moderate and transient. The hydrochlorothiazide component is responsible for most of the metabolic side effects (electrolyte disturbances, elevated uric acid, changes in blood glucose and lipids), while the candesartan component is associated with hyperkalaemia and, very rarely, angioedema. The high-strength 32 mg candesartan dose does not meaningfully increase the risk of candesartan-specific side effects compared with lower doses, because candesartan reaches near-maximal receptor blockade at 16 mg.
Common
- Dizziness or lightheadedness, especially on standing up quickly (orthostatic hypotension)
- Headache
- Fatigue and general weakness
- Increased frequency of urination (polyuria), particularly in the first few days of treatment
- Elevated blood uric acid levels (hyperuricaemia) – may trigger gout in susceptible individuals
- Mildly elevated blood glucose levels
- Mildly elevated cholesterol and triglyceride levels
- Low potassium (hypokalaemia) – symptoms may include muscle cramps, weakness, or palpitations
- Upper respiratory tract infections and viral illnesses
Uncommon
- Symptomatic hypotension, especially after the first dose or after dose adjustment
- Nausea, vomiting, or diarrhoea
- Abdominal pain or discomfort
- Skin rash, pruritus (itching), or urticaria
- Elevated blood creatinine and blood urea nitrogen (signs of reduced kidney function)
- Low sodium (hyponatraemia) – symptoms may include confusion, nausea, fatigue, or seizures in severe cases
- Back pain, muscle pain (myalgia), or joint pain (arthralgia)
- Impotence or reduced libido (more common with diuretics)
- Increased sensitivity to sunlight (photosensitivity)
Rare
- Angioedema (swelling of the face, lips, tongue, or throat) – seek immediate emergency care
- Severe allergic (anaphylactic) reactions
- Acute kidney injury or acute renal failure, particularly in dehydrated or volume-depleted patients
- Acute pancreatitis (inflammation of the pancreas)
- Hepatitis, cholestatic jaundice, or impaired liver function
- Blood disorders: leucopenia, neutropenia, thrombocytopenia, agranulocytosis, haemolytic anaemia
- Severe hyperkalaemia (dangerously high potassium) – particularly in patients with impaired renal function or concurrent potassium-elevating medications
- Interstitial nephritis associated with hydrochlorothiazide
- Acute myopia and secondary angle-closure glaucoma – typically within hours to weeks of starting treatment
- Acute respiratory toxicity, including non-cardiogenic pulmonary oedema
- Stevens-Johnson syndrome, toxic epidermal necrolysis, and cutaneous lupus erythematosus
- Electrolyte disturbances including hypomagnesaemia, hypochloraemia, and hypercalcaemia
Contact your doctor or emergency services immediately if you experience swelling of the face, lips, tongue, or throat (angioedema), severe dizziness or fainting, signs of severe allergic reaction (difficulty breathing, widespread rash, throat tightness), very fast or irregular heartbeat, sudden significant reduction in urine output, sudden vision changes or eye pain, yellow discoloration of the skin or eyes (jaundice), or signs of pancreatitis (severe upper-abdominal pain radiating to the back with persistent nausea and vomiting).
Long-term use of hydrochlorothiazide has been associated in several large epidemiological studies with a small but measurable increased risk of non-melanoma skin cancer, specifically basal cell carcinoma and squamous cell carcinoma. The risk is thought to be related to the photosensitising properties of thiazides and is dose- and duration-dependent, being most evident with cumulative doses above 50,000 mg. If you are taking Parapres Comp long-term, protect your skin from excessive sun and artificial UV exposure, use broad-spectrum sunscreen with SPF 30 or higher, wear protective clothing and wide-brimmed hats in sunny weather, and have any new or changing skin lesions examined by a dermatologist without delay.
How Should You Store Parapres Comp?
Store Parapres Comp tablets at room temperature below 30°C (86°F), in the original packaging, to protect the tablets from moisture and light. Keep all medicines out of the reach and sight of children. Do not use after the expiry date printed on the carton and blister strip.
Proper storage is essential to keep your medicine effective throughout its shelf life. Parapres Comp tablets should be kept in the original blister pack inside the outer carton until the time of use. Do not transfer the tablets to another container or decant them into a pill organiser for long periods, as this may accelerate degradation. Avoid storing the medication in the bathroom, kitchen, or car, where humidity and temperature fluctuations are common and can compromise the stability of the active ingredients.
Do not use Parapres Comp after the expiry date stated on the packaging. The expiry date refers to the last day of the month shown. Do not dispose of medicines via wastewater or household waste, as this contributes to water contamination and environmental damage. Ask your pharmacist how to dispose of medicines you no longer need; most countries operate pharmacy take-back schemes for unused medications. Proper disposal of pharmaceutical waste is an important part of protecting the environment and preventing accidental ingestion by others.
If your tablets appear discoloured, crumbled, broken, or otherwise different in appearance from how they were when the pack was new, do not take them. Return them to your pharmacy for safe disposal and obtain a replacement supply from your pharmacist.
What Does Parapres Comp Contain?
Each Parapres Comp tablet contains two active ingredients: candesartan cilexetil 32 mg and hydrochlorothiazide 12.5 mg, together with several inactive excipients that aid tablet formulation, stability, and absorption.
Active Ingredients
- Candesartan cilexetil 32 mg: A prodrug of candesartan, an angiotensin II receptor blocker (ARB). During absorption, candesartan cilexetil is rapidly hydrolysed to the active metabolite candesartan, which selectively and competitively blocks the angiotensin II AT1 receptor, reducing vasoconstriction, aldosterone release, and sodium retention.
- Hydrochlorothiazide 12.5 mg: A thiazide-type diuretic that inhibits the sodium-chloride cotransporter in the distal convoluted tubule of the nephron, promoting excretion of sodium, chloride, and water in the urine. The low 12.5 mg dose preserves most of the antihypertensive benefit of thiazides while minimising metabolic side effects.
Inactive Ingredients (Excipients)
The inactive ingredients in Parapres Comp tablets typically include:
- Calcium carmellose (carboxymethylcellulose calcium): A disintegrant that helps the tablet break apart in the gastrointestinal tract
- Hydroxypropylcellulose: A binder that holds the tablet together
- Lactose monohydrate: A filler and diluent – patients with rare galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption should not take this medicine
- Magnesium stearate: A lubricant used during the tablet manufacturing process
- Maize starch: Used as a filler and disintegrant
- Iron oxide (yellow and/or red, E172): Colouring agents used to visually distinguish different tablet strengths
- Macrogol (polyethylene glycol): Used in certain formulations as a processing aid or coating component
Parapres Comp tablets contain lactose monohydrate as an excipient. If your doctor has told you that you have an intolerance to certain sugars, contact your doctor before taking this medicine. The amount of lactose per tablet is small but can be relevant for individuals with severe lactose intolerance or congenital disorders of galactose metabolism.
Frequently Asked Questions About Parapres Comp
Parapres contains only candesartan cilexetil, an angiotensin II receptor blocker (ARB). Parapres Comp is a combination tablet that also contains hydrochlorothiazide, a thiazide diuretic, in the same pill as candesartan. Parapres Comp is prescribed when candesartan alone at its highest dose (32 mg) does not provide sufficient blood pressure control. Adding the diuretic component provides a complementary and synergistic mechanism of action, delivering greater blood pressure reduction than either drug used individually. Your doctor will typically start treatment with candesartan alone and only switch to Parapres Comp if additional blood pressure lowering is needed.
In many cases, yes. Parapres Comp is often combined with other antihypertensive medications for patients with resistant hypertension, most commonly with calcium channel blockers such as amlodipine, lercanidipine, or nifedipine. In some cases, a beta-blocker (such as bisoprolol) or a mineralocorticoid receptor antagonist (such as spironolactone) may also be added under specialist supervision. However, Parapres Comp should generally not be combined with ACE inhibitors (ramipril, enalapril) or direct renin inhibitors (aliskiren), because dual blockade of the renin-angiotensin-aldosterone system substantially increases the risk of hypotension, hyperkalaemia, and acute kidney injury without additional cardiovascular benefit. Always discuss all your medications with your doctor and pharmacist before starting any new treatment.
Parapres Comp begins lowering blood pressure within a few hours of the first dose. The diuretic effect of hydrochlorothiazide starts within approximately 2 hours and peaks around 4 hours, while the ARB effect of candesartan develops gradually over the first 24 hours. However, the full antihypertensive effect of the combination is usually reached after 4 to 6 weeks of continuous daily use. It is essential to keep taking the medication exactly as prescribed even if you feel well, because hypertension is typically asymptomatic. Do not stop the medication or alter your dose without consulting your doctor, as abrupt discontinuation can cause your blood pressure to rebound.
Dizziness, particularly when standing up quickly (orthostatic hypotension), is a common side effect, especially at the start of treatment, after a dose increase, during hot weather, or after alcohol consumption. If you feel dizzy, sit or lie down immediately until the feeling subsides. Always stand up slowly from sitting or lying positions. Make sure you are drinking enough fluids, because dehydration can amplify the effect. Avoid alcohol, and be cautious in hot environments such as saunas or during vigorous exercise. If dizziness persists, becomes severe, or is associated with fainting, contact your doctor, as your dose may need to be reduced or the medication may need to be reviewed.
Parapres Comp can affect kidney function, especially in patients who already have kidney problems, are dehydrated, or are taking other medications that affect the kidneys (such as NSAIDs). The candesartan component alters intrarenal haemodynamics by dilating the efferent arterioles, which can transiently reduce glomerular filtration, while the diuretic component reduces circulating blood volume. This is why your doctor will check your kidney function with blood tests (creatinine, eGFR) and potassium before starting treatment, typically 2–4 weeks after starting, and periodically thereafter. Small rises in creatinine (up to 30 percent) are expected and usually do not require stopping the medication. Contact your doctor promptly if you notice a significant decrease in urine output, unexplained swelling of the ankles, or persistent nausea and fatigue.
Yes, regular moderate exercise is strongly encouraged and is an important part of managing high blood pressure. However, be aware that the diuretic component of Parapres Comp increases fluid loss, so you should stay well hydrated before, during, and after exercise. Exercising in hot or humid weather requires extra caution, because excessive sweating combined with the diuretic effect can cause dehydration and electrolyte imbalances (low potassium, low sodium). If you experience unusual dizziness, weakness, muscle cramps, or palpitations during exercise, stop and rest, drink fluids containing electrolytes, and consult your doctor if symptoms persist or recur. Aim for at least 150 minutes of moderate aerobic exercise per week, as recommended by international hypertension guidelines.
There is no specific diet required for Parapres Comp, but lifestyle measures are essential for optimal blood pressure control. A diet low in sodium (less than 5–6 g of salt per day), rich in fruit, vegetables, whole grains, lean protein, and low-fat dairy (the DASH or Mediterranean diet) is strongly recommended. Avoid potassium-based salt substitutes and be cautious with large amounts of liquorice, which can raise blood pressure and cause potassium depletion. Moderate your alcohol intake, as alcohol can amplify the antihypertensive effect and increase the risk of dehydration. Maintain a healthy body weight, limit caffeine in sensitive individuals, and aim to quit smoking – these measures can often reduce the dose of blood pressure medication you need over time.
References
- European Medicines Agency (EMA). Summary of Product Characteristics for candesartan cilexetil/hydrochlorothiazide combinations. Available at: www.ema.europa.eu. Accessed February 2026.
- Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension. Journal of Hypertension. 2023;41(12):1874-2071. doi:10.1097/HJH.0000000000003480
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Journal of the American College of Cardiology. 2018;71(19):e127-e248.
- World Health Organization (WHO). Guideline for the pharmacological treatment of hypertension in adults. Geneva: WHO; 2021. Available at: www.who.int.
- National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management [NG136]. Updated 2022. Available at: www.nice.org.uk.
- Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334-1357.
- British National Formulary (BNF). Candesartan with hydrochlorothiazide. Available at: bnf.nice.org.uk. Accessed February 2026.
- Pedersen OD, Gustafsson F, Seibaek M, et al. Candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM) programme: an overview. The Lancet. 2003;362(9386):759-766.
- Sica DA, Carter B, Cushman W, Hamm L. Thiazide and loop diuretics. The Journal of Clinical Hypertension. 2011;13(9):639-643. doi:10.1111/j.1751-7176.2011.00508.x
- Pedersen SA, Gaist D, Schmidt SAJ, et al. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: a nationwide case-control study from Denmark. Journal of the American Academy of Dermatology. 2018;78(4):673-681.e9.
- U.S. Food and Drug Administration. Drug Safety Communication: FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil; review of hydrochlorothiazide skin cancer risk. 2020.
- Wang TY, Chen J, Kao CC, et al. Acute kidney injury with triple therapy of renin-angiotensin inhibitors, diuretics and NSAIDs: systematic review and meta-analysis. British Medical Journal. 2013;346:e8525. doi:10.1136/bmj.e8525
About Our Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, which comprises licensed specialist physicians in cardiology, clinical pharmacology, and internal medicine. Our team follows the GRADE framework for evidence evaluation and adheres to international guidelines from the ESC, ESH, AHA, WHO, and NICE.
All medical claims in this article are supported by peer-reviewed research, systematic reviews, and international clinical guidelines. We use the GRADE framework to evaluate evidence quality and strength of recommendations.
iMedic is editorially independent with no pharmaceutical sponsorship or advertising. Our content is created solely to provide accurate, evidence-based medical information to patients and caregivers worldwide.
Last medical review: by iMedic Medical Review Board
For more information about our editorial standards, visit our Editorial Standards page. To contact our medical team, visit our Contact page.